|
|
|
| Jul. 29, 2010 |
Amgen's Second Quarter 2010 Adjusted Earnings Per Share Increased 7 Percent to $1.38
|
| Jul. 28, 2010 |
2010 Addressing Psoriasis(TM) Contest Winners Attend a Style Consultation with Tim Gunn in New York City
|
| Jul. 26, 2010 |
Amgen Announces Webcast of 2010 Second Quarter Financial Results
|
| Jul. 22, 2010 |
Amgen Appoints Ronald D. Sugar to the Company's Board of Directors
|
| Jul. 19, 2010 |
Amgen Scholars' Summer Research Helps Lead to Science Careers
|
| Jul. 16, 2010 |
FDA Grants Priority Review Designation to Denosumab Biologics License Application for the Reduction of Skeletal Related Events in Advanced Cancer Patients
|
| Jul. 15, 2010 |
Amgen Appoints Jonathan M. Peacock Executive Vice President and Chief Financial Officer
|
| Jul. 14, 2010 |
Amgen Foundation and Changemakers Launch Global Online Competition to Empower Patients for Better Outcomes
|
| Jun. 22, 2010 |
34 Teachers and Schools Across North America Receive $10,000 Amgen Award for Science Teaching Excellence
|
| Jun. 15, 2010 |
Amgen to Present at the Goldman Sachs Global Healthcare Conference
|
| Jun. 7, 2010 |
Amgen to Present at the Jeffries Global Life Sciences Conference
|
| Jun. 6, 2010 |
New AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer
|
| Jun. 5, 2010 |
Striking the Balance: Community Experts Come Together for High-Level Dialogue on Cancer Care
|
| Jun. 5, 2010 |
Denosumab Demonstrated Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Prostate Cancer
|
| Jun. 5, 2010 |
New Analyses of Denosumab Pivotal Phase 3 Trials Reinforce Potential Advantages Over Standard of Care
|
| Jun. 4, 2010 |
New AMG 479 Phase 2 Data Show Antitumor Activity in Patients With Metastatic Pancreatic Cancer
|
| Jun. 1, 2010 |
FDA Approves Amgen's Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture
|
| May. 28, 2010 |
Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union
|
| May. 20, 2010 |
Amgen Highlights Key Clinical Data to Be Presented at American Society of Clinical Oncology Annual Meeting
|
| May. 14, 2010 |
Amgen Submits Denosumab Biologics License Application to FDA for the Reduction of Skeletal Related Events in Cancer Patients
|
| May. 12, 2010 |
Amgen Announces Voting Results of Annual Meeting of Stockholders
|
| May. 11, 2010 |
Amgen's Breakaway From Cancer(R) to Honor Cancer Survivors at Amgen Tour of California
|
| May. 6, 2010 |
Amgen Scientists Visit Biotechnology Classrooms Across the Country in Support of National Lab Day
|
| Apr. 29, 2010 |
Amgen to Present at the Deutsche Bank 35th Annual Healthcare Conference
|
| Apr. 26, 2010 |
Amgen Appoints Robert A. Bradway President and Chief Operating Officer
|
| Apr. 21, 2010 |
Amgen's First Quarter 2010 Adjusted Earnings Per Share Increased 20 Percent to $1.30
|
| Apr. 19, 2010 |
Amgen Announces Webcast of 2010 First Quarter Financial Results
|
| Apr. 19, 2010 |
Amgen Preclinical Study Demonstrated Anti-Tumor Activity in Mammary Tumor Model
|
| Apr. 18, 2010 |
Analysis of Vectibix(R) Study Using New Gene Technology Helps to Advance Prospects for Personalized Medicine
|
| Apr. 12, 2010 |
Amgen Highlights Biomarker and Preclinical Data to be Presented at American Association for Cancer Research (AACR) Annual Meeting
|
| Mar. 8, 2010 |
Amgen to Present at the Cowen and Company 30th Annual Healthcare Conference
|
| Mar. 3, 2010 |
'Project Runway's' Tim Gunn Returns to Address Psoriasis(TM) and Empower Patients to be Confident in Their Personal Style
|
| Feb. 19, 2010 |
FDA Classifies Prolia(TM) (Denosumab) Complete Response Submission and Targets Action Date
|
| Feb. 16, 2010 |
Amgen and Centocor Ortho Biotech Products Finalize ESA Risk Evaluation and Mitigation Strategy (REMS) With FDA
|
| Feb. 8, 2010 |
Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases
|
| Jan. 25, 2010 |
Amgen's Fourth Quarter 2009 Adjusted Earnings Per Share Decreased 1 Percent to $1.05; Full Year 2009 Adjusted Earnings Per Share Increased 8 Percent to $4.91
|
| Jan. 21, 2010 |
Amgen Presents Complete Results From Two Pivotal Phase 3 Studies of Vectibix(R) at Gastrointestinal Cancers Symposium
|
| Jan. 20, 2010 |
Amgen Announces Webcast of 2009 Fourth Quarter and Full Year Financial Results
|
| Jan. 14, 2010 |
Amgen Donates $2 Million, Establishes Earthquake Relief Program
|
| Jan. 7, 2010 |
Amgen to Present at the 28th Annual JP Morgan Healthcare Conference
|
